Stockscreener 앱 받기
1.25
12.61%
0.14
시장 영업 전:
1.25
전일 마감가:
$1.11
열려 있는:
$1.1
하루 거래량:
5.75M
Relative Volume:
2.61
시가총액:
$151.84M
수익:
$13.45M
순이익/손실:
$-178.23M
주가수익비율:
-0.7576
EPS:
-1.65
순현금흐름:
$-132.53M
1주 성능:
+35.24%
1개월 성능:
+36.78%
6개월 성능:
-60.32%
1년 성능:
-73.90%
1일 변동 폭
$1.10
$1.39
1주일 범위
$0.9301
$1.39
52주 변동 폭
$0.6611
$5.92
Fate Therapeutics Inc Stock (FATE) Company Profile
명칭
Fate Therapeutics Inc
전화
858.875.1803
주소
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
FATE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
1.25 | 151.84M | 13.45M | -178.23M | -132.53M | -1.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-18 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-06-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Wells Fargo | Equal Weight |
| 2023-01-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-01-06 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-01-06 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2023-01-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-01-06 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-01-06 | 다운그레이드 | Truist | Buy → Hold |
| 2023-01-06 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-12-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-12-15 | 개시 | Goldman | Sell |
| 2022-11-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-10-10 | 개시 | Canaccord Genuity | Buy |
| 2022-08-18 | 재개 | Wells Fargo | Overweight |
| 2022-07-28 | 개시 | Needham | Hold |
| 2022-07-11 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2022-06-03 | 개시 | Robert W. Baird | Neutral |
| 2022-02-11 | 재개 | BMO Capital Markets | Market Perform |
| 2021-12-15 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-12-07 | 개시 | Cowen | Outperform |
| 2021-11-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-26 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-06-07 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-05-07 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-04-26 | 재개 | Jefferies | Buy |
| 2021-02-26 | 개시 | BofA Securities | Buy |
| 2021-02-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-02-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-27 | 재개 | H.C. Wainwright | Neutral |
| 2020-05-13 | 개시 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-09 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2019-12-30 | 재확인 | Mizuho | Buy |
| 2019-12-09 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-06 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2019-10-01 | 개시 | Stifel | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-07-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 개시 | Oppenheimer | Outperform |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-06-07 | 개시 | ROTH Capital | Neutral |
| 2019-05-31 | 개시 | Guggenheim | Buy |
| 2019-05-24 | 재개 | Citigroup | Buy |
| 2019-03-28 | 개시 | SVB Leerink | Outperform |
| 2019-01-03 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2018-11-05 | 개시 | Jefferies | Buy |
| 2018-08-01 | 개시 | Citigroup | Buy |
| 2018-03-06 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
모두보기
Fate Therapeutics Inc 주식(FATE)의 최신 뉴스
Is Fate Therapeutics Inc (NASDAQ:FATE) stock a better investment at this time? - uspostnews.com
The Attractiveness of Investing In Fate Therapeutics Inc (FATE) is Growing - knoxdaily.com
Franklin Resources Inc. Has $273,000 Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Vanguard Group Inc. Cuts Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag - MSN
Fate Therapeutics gets RMAT status from FDA for Lupus treatment - MSN
Fate Therapeutics’ iPSC-derived CAR-T FT819 Nabs FDA RMAT Designation for Lupus - CGTLive®
Fate Therapeutics’ new CAR T-cell therapy fast-tracked by FDA - Investing.com South Africa
Fate Therapeutics receives RMAT designation from FDA for FT819 - TipRanks
Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic - MSN
Fate Therapeutics gets RMAT status from FDA for lupus treatment - Seeking Alpha
Fate Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy Designation for Lupus Cell Therapy; Shares Fall - marketscreener.com
Fate Therapeutics, Inc. Receives Regenerative Medicine Advanced Therapy Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus - marketscreener.com
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) - GlobeNewswire
American Century Companies Inc. Buys 12,295 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World
NK Cells Market Hits New High | Major Giants NantKwest, Fate Therapeutics, Affimed, Glycostem, Nkarta - openPR.com
Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by Prudential Financial Inc. - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Recommendation of “Hold” from Analysts - Defense World
Fate Therapeutics, Inc. (NASDAQ:FATE) Stock Position Decreased by Thrivent Financial for Lutherans - Defense World
Fate Therapeutics (FATE) Down 34.6% Since Last Earnings Report: Can It Rebound? - MSN
Fate Therapeutics (NASDAQ:FATE) Stock Crosses Below 200 Day Moving Average – Here’s What Happened - Defense World
FATE CLASS ACTION: Hagens Berman Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Pending - ACCESS Newswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Fate Therap stock hits 52-week low at $0.87 amid sharp decline - Investing.com
FY2025 EPS Forecast for Fate Therapeutics Raised by Analyst - The AM Reporter
Equities Analysts Issue Forecasts for FATE FY2025 Earnings - Defense World
Weekly Research Analysts’ Ratings Updates for Fate Therapeutics (FATE) - Defense World
Fate Therapeutics Inc. Faces Global Expansion Challenges Amid Political and Economic Uncertainties - MSN
Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa
Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com
Fate Therapeutics at Leerink Conference: Strategic Shift to FT-819 By Investing.com - Investing.com UK
Fate Therapeutics at Barclays Conference: Strategic Shift to Autoimmune Focus - Investing.com UK
Q1 Earnings Estimate for Fate Therapeutics Issued By Wedbush - The AM Reporter
Fate Therapeutics (NASDAQ:FATE) Rating Lowered to “Sell” at StockNews.com - Defense World
Fate Therapeutics price target lowered to $2.50 from $3 at BofA - TipRanks
Q1 EPS Estimates for Fate Therapeutics Boosted by Wedbush - Defense World
Fate Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price Target - Yahoo Finance
Stifel Nicolaus Lowers Fate Therapeutics (NASDAQ:FATE) Price Target to $3.00 - Defense World
Wedbush Reaffirms Neutral Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World
Needham & Company LLC Reiterates Hold Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World
Wells Fargo & Company Has Lowered Expectations for Fate Therapeutics (NASDAQ:FATE) Stock Price - Defense World
Is Fate Therapeutics Inc (NASDAQ: FATE) A Good Investment For New Investors Now? - Stocks Register
Optimistic Outlook for Fate Therapeutics’ FT819 in Cell-Therapy Space Amid Promising Phase 1 Results - TipRanks
Cautious Outlook on Fate Therapeutics Amid FT819 Program Developments and Financial Uncertainties - TipRanks
Jefferies cuts Fate Therapeutics target to $8, keeps Buy rating By Investing.com - Investing.com Canada
Stifel cuts Fate Therapeutics stock target to $3, maintains hold By Investing.com - Investing.com Canada
Fate Therapeutics Inc (FATE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
4.32%
자본화:
|
볼륨(24시간):